Kymera Therapeutics, Inc. (KYMR) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Kymera Therapeutics reported revenue of $39.2M, down 16.7% from $47.1M the year before. Net income was -$311.4M (a -794.0% net margin), or -$3.69 per diluted share. Gross margin was 0.0% and operating margin was -891.1%. Operating activities generated -$232.9M of cash, leaving -$234.3M of free cash flow. At fiscal year end, Kymera Therapeutics held $1.74B in total assets against $163.1M in total liabilities, including $357.0M of cash and equivalents.
Open the full interactive Kymera Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Kymera Therapeutics Key Stats
| Share Price | $106.68 |
|---|---|
| Market Cap | $10.47B |
| Revenue YoY Growth | -16.7% |
| 52-Week Range | $55.80 – $127.31 |
| Shares Outstanding | 98.2 million (basic, 2026 Q2) |
Kymera Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Gross Profit | — | — | — | — | $0 | $0 |
| Operating Income | -$46.3M | -$100.5M | -$161.3M | -$165.5M | -$261.6M | -$349.4M |
| Pre-Tax Income | -$45.6M | -$100.2M | -$154.8M | -$147.0M | -$223.9M | -$311.4M |
| Income Tax | $0 | $0 | $0 | — | — | $0 |
| Net Income | -$45.6M | -$100.2M | -$154.8M | -$147.0M | -$223.9M | -$311.4M |
| Diluted EPS | -$3.15 | -$2.09 | -$2.87 | -$2.52 | -$2.98 | -$3.69 |
Kymera Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.8M | $2.9M | $34.4M | $65.0M |
| Net Income | -$82.2M | -$87.0M | -$69.2M | -$61.2M |
| Diluted EPS | -$0.94 | -$1.03 | -$0.71 | -$0.62 |
Kymera Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $31.0M | $48.0M | $68.4M | $110.0M | $120.3M | $357.0M |
| Current Assets | $302.3M | $451.3M | $419.4M | $405.3M | $510.3M | $871.2M |
| Total Assets | $487.2M | $605.9M | $603.1M | $575.8M | $978.0M | $1.74B |
| Current Liabilities | $110.6M | $92.5M | $71.3M | $85.7M | $67.8M | $83.2M |
| Total Liabilities | $203.3M | $146.3M | $113.0M | $180.8M | $142.4M | $163.1M |
| Shareholders' Equity | $283.9M | $459.6M | $490.2M | $395.0M | $835.6M | $1.58B |
Kymera Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $88.1M | -$128.9M | -$153.1M | -$102.8M | -$194.5M | -$232.9M |
| Cash From Investing | -$422.6M | -$99.8M | $20.5M | $139.9M | -$404.1M | -$521.1M |
| Cash From Financing | $289.3M | $250.3M | $153.0M | $4.2M | $608.9M | $990.7M |
| Free Cash Flow | $79.0M | -$130.5M | -$155.9M | -$137.3M | -$207.3M | -$234.3M |
Figures from Kymera Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Kymera Therapeutics financials page for every line item.
Kymera Therapeutics Company Profile
| Ticker | KYMR |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Watertown, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001815442 |
Frequently Asked Questions
What was Kymera Therapeutics' revenue in fiscal 2025?
Kymera Therapeutics (KYMR) reported revenue of $39.2M for fiscal 2025.
What is Kymera Therapeutics' annual revenue history?
Kymera Therapeutics' annual revenue by fiscal year: 2020: $34.0M; 2021: $72.8M; 2022: $46.8M; 2023: $78.6M; 2024: $47.1M; 2025: $39.2M.
What was Kymera Therapeutics' net income in fiscal 2025?
Kymera Therapeutics reported net income of -$311.4M for fiscal 2025.
What was Kymera Therapeutics' earnings per share (EPS) in fiscal 2025?
Kymera Therapeutics' diluted EPS was -$3.69 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Kymera Therapeutics generate in fiscal 2025?
Kymera Therapeutics generated -$234.3M of free cash flow in fiscal 2025.
What was Kymera Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Kymera Therapeutics reported revenue of $65.0M.
How many shares of Kymera Therapeutics are outstanding?
Kymera Therapeutics reported a weighted average of 98.2 million basic shares outstanding in 2026 Q2.
What is Kymera Therapeutics' market cap?
Based on its latest closing price, Kymera Therapeutics (KYMR) has a market capitalization of about $10.47B.
When does Kymera Therapeutics' fiscal year end?
Kymera Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Kymera Therapeutics headquartered?
Kymera Therapeutics lists its business address in Watertown, Massachusetts in its SEC filings.
Kymera Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →